Dr. Reginald Seeto Appointed as CEO and President, to Lead Scipher Medicine's Next Phase of Growth [Yahoo! Finance]
CareDx, Inc. (CDNA)
Last caredx, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.caredxinc.com
Company Research
Source: Yahoo! Finance
Scipher developed Spectra TM , a proprietary AI platform that has been used to build both an autoimmune diagnostic and an emerging biopharmaceutical business. In the diagnostics business, PrismRA ® was recently approved by MolDx for therapy selection in rheumatoid arthritis patients, and in the biopharmaceutical business, recent deals have focused on generating novel target discovery and data insights for partners. Dr. Seeto is a seasoned CEO and Board Member who brings more than two decades of leadership experience across both diagnostic and therapeutic companies. "Reg has an established leadership track record in building both products and companies by setting bold strategies that can be delivered through high performing teams. His deep understanding of the diagnostic and therapeutic industry makes him the right person to lead Scipher going forward," said Samir Kaul, Managing Director at Khosla Ventures and a member of the Scipher Board of Directors. Dr. Seeto was most recentl
Show less
Read more
Impact Snapshot
Event Time:
CDNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDNA alerts
High impacting CareDx, Inc. news events
Weekly update
A roundup of the hottest topics
CDNA
News
- CareDx, Inc (NASDAQ: CDNA) had its price target raised by analysts at Craig Hallum from $15.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies [Yahoo! Finance]Yahoo! Finance
- Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer BiopsiesBusiness Wire
- CareDx, Inc (NASDAQ: CDNA) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- CareDx, Inc (NASDAQ: CDNA) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.MarketBeat
CDNA
Earnings
- 5/9/24 - Beat
CDNA
Sec Filings
- 5/16/24 - Form 4
- 5/9/24 - Form POS
- 5/9/24 - Form 10-Q
- CDNA's page on the SEC website